Another Late-Stage Firm with Impressive Technology and Promising Products

About Iovance Biotherapeutics
Iovance Biotherapeutics (IOVA) is a late-stage biotechnology company developing novel cancer immunotherapies based on its tumor-infiltrating lymphocyte (TIL) technology. Iovance announced promising updates from ongoing clinical trials in advanced cervical cancer and advanced melanoma.

The data will be presented at the 55th Annual . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.